KOCITAF
Kocitaf is one of the PEP medications (post-exposure prophylaxis) used in the treatment and prevention of HIV. Each tablet of Kocitaf contains a combination of three active ingredients: Dolutegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate. Dolutegravir inhibits HIV integrase, an enzyme essential for the replication of the virus, by blocking the process of viral DNA integration. Emtricitabine and Tenofovir Alafenamide Fumarate, both are nucleoside reverse transcriptase inhibitors (NRTIs), work by incorporating into viral DNA and terminating its replication.
Kocitaf is taken once daily and should be started as soon as possible, and not later than 72 hours after potential exposure to HIV. It is important to follow the prescribed dosage and complete the full course of treatment to effectively prevent the development of HIV infection.
Kocitaf is one of the PEP medications (post-exposure prophylaxis) used in the treatment and prevention of HIV. Each tablet of Kocitaf contains a combination of three active ingredients: Dolutegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate. Dolutegravir inhibits HIV integrase, an enzyme essential for the replication of the virus, by blocking the process of viral DNA integration. Emtricitabine and Tenofovir Alafenamide Fumarate, both are nucleoside reverse transcriptase inhibitors (NRTIs), work by incorporating into viral DNA and terminating its replication.
Kocitaf is taken once daily and should be started as soon as possible, and not later than 72 hours after potential exposure to HIV. It is important to follow the prescribed dosage and complete the full course of treatment to effectively prevent the development of HIV infection.
Kocitaf is one of the PEP medications (post-exposure prophylaxis) used in the treatment and prevention of HIV. Each tablet of Kocitaf contains a combination of three active ingredients: Dolutegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate. Dolutegravir inhibits HIV integrase, an enzyme essential for the replication of the virus, by blocking the process of viral DNA integration. Emtricitabine and Tenofovir Alafenamide Fumarate, both are nucleoside reverse transcriptase inhibitors (NRTIs), work by incorporating into viral DNA and terminating its replication.
Kocitaf is taken once daily and should be started as soon as possible, and not later than 72 hours after potential exposure to HIV. It is important to follow the prescribed dosage and complete the full course of treatment to effectively prevent the development of HIV infection.